1197-22-4 | N-Phenylmethanesulfonamide

Packsize	Purity	Availability	Price	Discounted Price
1g	95%	in stock	$17.00	$12.00
5g	95%	in stock	$24.00	$17.00
10g	98%	in stock	$33.00	$23.00
25g	98%	in stock	$65.00	$45.00
100g	98%	in stock	$228.00	$160.00
500g	98%	in stock	$938.00	$657.00

Description

• Catalog Number: AA32808
• Chemical Name: N-Phenylmethanesulfonamide
• CAS Number: 1197-22-4
• Molecular Formula: C7H9NO2S
• Molecular Weight: 171.2169
• MDL Number: MFCD00043782
• SMILES: CS(=O)(=O)Nc1ccccc1
• NSC Number: 11329

Computed Properties

• Complexity: 199
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 0.9

Literature

• Iguratimod: a new disease-modifying antirheumatic drug.

  Drugs of today (Barcelona, Spain : 1998) 20120901

• Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes.

  Bioorganic & medicinal chemistry 20120715

• Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review.

  TheScientificWorldJournal 20120101

• Pharmacological management of atrial fibrillation: one, none, one hundred thousand.

  Cardiology research and practice 20110101

• In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel.

  PloS one 20110101

• Stereoselective Inhibition of the hERG1 Potassium Channel.

  Frontiers in pharmacology 20100101

• Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

  Biochemical pharmacology 20090515

• Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.

  Bioorganic & medicinal chemistry 20090115

• Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes.

  PloS one 20090101

• N-(4-Chloro-2-nitro-phen-yl)methane-sulfonamide.

  Acta crystallographica. Section E, Structure reports online 20081001

• Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.

  Cardiology journal 20080101

• Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

  Biochemical pharmacology 20070801

• Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores.

  Bioorganic & medicinal chemistry 20061001

• Expression and functional phenotype of mouse ERG K+ channels in the inner ear: potential role in K+ regulation in the inner ear.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050921

• Structural determinants of HERG channel block by clofilium and ibutilide.

  Molecular pharmacology 20040801

• A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells.

  American journal of physiology. Heart and circulatory physiology 20040501

• Acceleration of human myoblast fusion by depolarization: graded Ca2+ signals involved.

  Development (Cambridge, England) 20030801

• Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency.

  Cardiovascular research 20030301

• Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.

  Molecular pharmacology 20011201

• Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes.

  The Journal of pharmacy and pharmacology 20011201

• An amino acid residue whose change by mutation affects drug binding to the HERG channel.

  FEBS letters 20011012